Symbols

HUMA

Humacyte·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Consensus Rating "Strong Buy"

Gap Down

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About HUMA

Humacyte, Inc.

A clinical-stage biotech platform company that develops universally implantable bioengineered human tissues, complex tissue systems, and organs

Industry

Biological Technology

Established Date

07/01/2020

Listing Date

12/01/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

184

Fiscal Year Ends

12-31

Website

www.humacyte.com

Security Type

Common stock

Office address

2525 East North Carolina Highway 54 Durham NC 27713

Business

Introduction

Humacyte, Inc., was incorporated in Delaware on July 1, 2020. The company is a commercialization stage biotechnology platform company dedicated to the development of universally implantable bioengineered human tissue on a commercial scale. Its main product, Symvess, is a cell-free tissue-engineered blood vessel approved by the US Food and Drug Administration for vascular catheters in the event of limb artery injury. The company is also developing a similar product line for other vascular and non-vascular applications.

Company Financials

EPS

HUMA has released its 2025 Q4 earnings. EPS was reported at -0.13, versus the expected -0.13, meeting expectations. The chart below visualizes how HUMA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

HUMA has released its 2025 Q4 earnings report, with revenue of 467.00K, reflecting a YoY change of NaN%, and net profit of -24.80M, showing a YoY change of -18.45%. The Sankey diagram below clearly presents HUMA's revenue sources and cost distribution.